Shubhankar Nath, Ph.D. Boston, MA • (512) 618-1405 • [email protected] https://www.linkedin.com/in/shubhankarnath2000/ ImmunologyCell Biology Oncology Ph.D. in immunology with 2+ years of academic postdoctoral experience along with 1+ years of industry experience and expertise in immuno-oncology, T cell Biology, immunological pathways and signal transduction, molecular biology, biochemistry, pre-clinical in vitro drug screening utilizing primary mouse and human cells. Scientifically sophisticated professional with a strong history of effective design, execution, improvement, and troubleshooting of in vitro drug screening workflows through critical thinking, creative problem-solving skills, and experimentation and statistical data analysis. Instrumental in multiple collaborative projects with academic, government, and industry partners. Collaborative communicator with strong presentation skills and success motivating teams and training new researchers. Able to direct multiple tasks effectively and master innovative techniques. Driven to continuously improve and learn new techniques and technology. Cell Signalling •T Cell Cytotoxicity Assay •Protein Estimation •Cell Differentiation and Proliferation Assays •Cytokine Measurements •Innate Immunity •Multiplex-Assays •Cell Sorting •MSD •Density-gradient Enrichment EDUCATION AND TRAINING Ph.D. in Immunology The University of Texas at Austin Austin, TX 2016 M.S. in Microbiology Texas State University, San Marcos San Marcos, TX 2009 Bachelor’s in Veterinary Medicine and Animal Husbandry (DVM equivalent) WBUAFS Kolkata, India 2007 PROFESSIONAL EXPERIENCE Senior Oncology Scientist (2018 – Present) CELLINK LLC, Boston, MA Develop 3D bio-printed models of cancers, including lung, colon, breast, and pancreatic cancers for high-throughput screening of anti-cancer drugs and to study drug resistance mechanisms. Compose experimental protocols, application notes, white papers, and knowledge base articles. Lead product development, including design concepts, troubleshooting, conducting cellular assays, performance evaluation, statistical data analysis, and design for manufacturability and scale-up. Collaborate with interdisciplinary team of scientists and engineers from academia, government agencies, and industry partners. Key Achievements: . Demonstrated predictable value of 3D culture in cancer drug screening over 2D culture. Conceived and developed a series of ECM dissociation solution (Cell CollectTM) for downstream applications. Formulated and commercialized bioinks using physiologically relevant ECM for 3D bio-printing of human tissue and organs to facilitate regenerative medicine investigations. Developed 3D bio-printed platform for various applications, such as iPSC-derived 3D organoid models for respiratory diseases, cancer drug screening, immune checkpoint therapy, and ADC screening in collaboration with multiple pharmaceutical partners, including MedImmune/AstraZeneca. Postdoctoral Research Fellow (2016-2018) MGH, Harvard Medical School, Boston, MA Design and execute mechanism of action and biomarker studies, as well as combination studies for Bristol Myers Squibb’s preclinical-stage small molecule/IO drugs using in vitro methods, such as T cell assays, cytokine profiling, cell sorting, multi-color flow cytometry, gene expression analysis. Maintained mouse colony to create fluorescent OT- 1 T cells, harvested and cultured primary murine and human T cells, created specific antigen-expressing tumor cell lines. Developed several tumor models to study targeted therapy to overcome drug resistance. Wrote original manuscripts, IRB protocols, IACUC protocols, SOPs, and NIH grants. Shubhankar Nath, Ph.D. Page | 2 Key Achievements: . Developed high-content imaging-based 3D assays to evaluate Bristol-Myers Squibb’s proprietary immune checkpoint drug pipelines. Demonstrated the role of fluidic shear stress on drug resistance in ovarian cancer using a microfluidic model and evaluated EGFR-targeted photodynamic therapy (PDT) to overcome the resistance. Examined the translational potential of light-activated targeted nanomedicine using patient-derived xenograft (PDX) models of pancreatic cancer and glioma with an inter-disciplinary team of chemist, clinicians, and engineers in a hospital setting. Published 7 articles (5 first-authored), 1 invited book chapter, and 10+ conference presentations Graduate Researcher (Ph.D.) (2009 – 2016) The University of Texas at Austin, Austin, TX Investigated the mechanism of T cell focused secretion. Used human NK and T cell lines as well as OT-1 transgenic mouse primary T cells to confirm that the dynein and its accessory proteins play a central role in MTOC translocation in T cells, as opposed to the previously proposed actin-based MTOC model. Managed laboratory operations, including overseeing the use of laboratory funds and inventory. Trained students and fellow researchers in specialized lab techniques, served as a lab safety officer and wrote SOPs. Presented proposals, status reports, and final project reports. Key Achievements: . Designed and coordinated multiple hypothesis-driven studies to investigate the mechanisms of T cell focused secretion and identified two distinct pathways that coordinate the process. Identified and characterized several neurodevelopmental proteins to have an essential function in immune regulation in Schizophrenic patients by creating knock-out cell lines using CRISPR/Cas9 technologies. Created more than 30 vector constructs to express recombinant proteins in T cells and tumor cells to study protein-protein interaction during T cell-mediated killing of the cancer cells. Discovered the process of recruitment of three neurodevelopmental proteins, NDE1 (nuclear distribution E), Lis1 (lissencephaly 1) and DISC1 (disrupted in schizophrenia 1) to the immunological synapse of activated T cells. Mentored more than 10 undergraduate students and two Ph.D. rotation students on their independent projects from concept to completion. Graduate Researcher (M.S.) (2007 – 2009) Texas State University, San Marcos, TX Investigated the role of bacterial biofilms to protect pathogenic viruses from disinfectants and physical treatment. Conducted literature reviews, developed research protocols, maintained bacterial and viral stocks, and assisted undergraduate students in performing research. Key Achievements: . Investigated how biofilms protect pathogenic viruses from anti-microbial agents using RT-qPCR and plate- based assays, resulting in a first-author paper. Used transmission electron microscopy (TEM) and confocal microscopy to study biofilms-virus interactions. TECHNICAL PROFICIENCIES Molecular Biology. PCR, RT-qPCR, Cloning, Site-directed Mutagenesis, Designing Plasmids Molecular Biology: and Lentiviral Vectors, Transfection, Inducible and Stable Reporter Cell Line Generation, RNAi (shRNA, siRNA), Phage-Display Mouse and Human Primary and Immune Cell Culture, Density-gradient Enrichment, Cell Biology: Cytotoxicity and Cell Signaling Assays, Multi-parametric FACS analysis and cell sorting, Immunofluorescence, Immunohistochemistry, Cell Differentiation and Proliferation Assays Microscopy: Microscopy. Confocal microscopy, High-Content Imaging, Transmission Electron Microscopy. Shubhankar Nath, Ph.D. Page | 3 Multiplex assays, Expression and Purification of Recombinant Proteins in E.coli and Biochemistry: Mammalian Cells, Protein Estimation, Western blots, Co-IP, ELISA, MTT/MTS assay, SDS- PAGE, UV-Vis, HPLC, FPLC, DLS, Radio-Isotope Handling, MSD 3D Organoid and Spheroid Models, Matrigel and Other Matrix/Bioink-based 3D Bio-printing, 3D Cell Culture: Biofabrication and Tissue Engineering, hiPSC-based organ printing and regeneration. Histology: Tissue collection, Preservation, Cryosectioning, Histological staining. Computational Office 365, Adobe Illustrator and Photoshop, GraphPad Prism, ImageJ/Fiji, Amira, CAD, skills: Origin, Sigma Plot, D-plot, FlowJo, Harmony, R Scripts. Creative Problem Solving, Project and People Management, Scientific Writing, Adaptability, Transferable skills: Strong Written and Verbal Communication. SELECTED PUBLICATIONS Maskalenko, N., S. Nath, et al., 2020. The DISC1-Girdin complex: A missing link in signaling to the T cell cytoskeleton Journal of Cell Science. Accepted. Pal, S.*, S. Nath* (co-first), et al., 2020. Emerging roles of mast cells in the regulation of lymphatic immuno- physiology. Frontiers in Immunology. Accepted. Nath, S., et al., 2020. Flow-induced Shear Stress Confers Resistance to Carboplatin in an Adherent Three- Dimensional Model for Ovarian Cancer: A Role for EGFR-Targeted Photoimmunotherapy Informed by Physical Stress. Journal of Clinical Medicine. 9: 924. Nath, S., et al., 2019. The course of immune stimulation by Photodynamic Therapy: Bridging fundamentals of photochemically-induced immunogenic cell death to the enrichment of T cell repertoire. Photochemistry and Photobiology. 95: 1288-1305. Nath, S., et al., 2019. Photoimmunotherapy of ovarian cancer: a unique niche in the management of advanced disease. Cancers. 11: 1887. Kercher, E., Nath, S., et al., 2019. Cancer cell-targeted and activatable photoimmunotherapy spares T cells in a 3D co-culture model. Photochemistry and Photobiology. 96: 295-300. Nath, S. and Moore, K. 2019. Photodynamic Therapy in a 3D model of ovarian cancer. Bio-protocol. 9: e3314. Rizvi, I., Nath., S., et al., 2018. A combination of Visudyne and a lipid-anchored liposomal formulation of benzoporphyrin derivative enhances photodynamic therapy efficacy in a 3D